View Older Stories View More Recent Stories
-
Amarin Corp. (AMRN) Appoints Erin Enright and Alfonso Zulueta to its Board, Announces Leadership Changes
-
Amarin Corp. (AMRN) Appoints Erin Enright and Alfonso Zulueta to its Board, Announces Leadership Changes
-
Amarin Corp. (AMRN) Appoints Erin Enright and Alfonso Zulueta to its Board, Announces Leadership Changes
-
Amarin Corp. (AMRN) Appoints Erin Enright and Alfonso Zulueta to its Board, Announces Leadership Changes
-
Amarin Corp. (AMRN) Appoints Erin Enright and Alfonso Zulueta to its Board, Announces Leadership Changes
-
Amarin Announces Appointment of New Directors and Board Leadership Changes
-
Amarin Announces Appointment of New Directors and Board Leadership Changes
-
Pre-Open Stock Movers 01/25: (CKPT) (SDC) (AMRN) Higher; (AJRD) (GE) (NVDA) Lower (more...)
-
After-Hours Stock Movers 01/24: (SDC) (AMRN) (IBM) Higher; (DCPH) (CHKP) (SAIL) Lower (more...)
-
Pre-Open Stock Movers 10/05: (MYOK) (KOS) (EIDX) Higher; (BBIO) (AMC) (DKNG) Lower (more...)
-
Amarin Corporation (AMRN) is a Likely Beneficiary From Teva Ruling, Citi Reiterates Buy
-
GSK v. Teva 'Skinny Label' Ruling Positive for Amarin (AMRN) - Citi
-
Amarin Corporation (AMRN) Top Line Weakens As Investors Wait for Patent Appeal Ruling - Citi
-
Amarin Corporation (AMRN) Litigation Decision Expected in March, Possible Catalyst This Friday - Citi
-
Pre-Open Stock Movers 02/18: (LM) (BEN) (AAP) Higher; (FLR) (CAG) (CVU) Lower (more...)
-
Citi Upgrades Amarin Corporation (AMRN) to Buy, Anticipates Strong Sales Growth
-
Citi Would Buy Amarin (AMRN) Over The Medicines Company (MDCO)
-
Citi Downgrades Amarin Corporation (AMRN) to Neutral
-
Amarin Corporation (AMRN) Could Have 20% Upside Over the Next Week - Citi
-
Amarin (AMRN) and Sarepta (SRPT) Added to Citi Top 5 Biotechs List
-
KOLs See Potential Market for Amarin's (AMRN) Vascepa as 'Very Large' - Citi
-
Amarin to Participate in a Fireside Chat at Citi’s 14th Annual Biotech Conference
-
Amarin to Participate in a Fireside Chat at Citi’s 14th Annual Biotech Conference
-
Amarin Corporation (AMRN) May See Pressure From New AHA Advisory - Citi
-
Amarin Corporation's (AMRN) FDA Review is on Track, 2020 Should See Acceleration - Citi
-
Pre-Open Movers 07/02: (EROS) (AMRN) (DOVA) Higher; (OCX) (AYI) (BL) (more...)
-
Amarin Corporation (AMRN) PT Raised to $23 at Citi Ahead of 5 Catalysts
-
Amarin Corporation (AMRN) PT Lowered to $20 at Citi
-
Amarin to Participate in a Fireside Chat at Citi’s 2018 Global Healthcare Conference
-
Amarin to Participate in a Fireside Chat at Citi’s 2018 Global Healthcare Conference
-
Amarin Corp. (AMRN) Sees Sharp Green-to-Red Reversal
-
Pre-Open Movers 11/14: (CLD) (PETQ) (AMRN) Higher; (AMRS) (PCG) (MCD) Lower (more...)
-
UPDATE: Citi Upgrades Amarin Corporation (AMRN) to Buy
-
Citi Downgrades Amarin Corporation (AMRN) to Neutral
-
Amarin Corporation (AMRN) PT Raised to $25 at Citi
-
Pre-Open Movers 10/04: (BKS) (CLDR) (HDP) Higher; (RTEC) (WLDN) (SNAP) Lower (more...)
-
UPDATE: Amarin Corporation (AMRN) PT Raised to $17 at Citi
-
UPDATE: Amarin Corp. (AMRN) Has ~5X Upside - Citi
-
Pre-Open Movers 06/27: (CGIX) (ARNA) (DRI) Higher; (ALDR) (FNJN) (NEOS) Lower (more...)
-
Citi Starts Amarin Corporation (AMRN) at Buy
-
Amarin Corp plc (AMRN) Boosts Offering to 24.3M, Priced at $2.85/ADS
-
Amarin Announces Underwriters’ Exercise of Option to Purchase Additional American Depositary Shares
-
Amarin Corp plc (AMRN) Prices 21.1M Offering at $2.85/ADS
-
Amarin Prices Public Offering of American Depositary Shares
-
Amarin Corp plc (AMRN) Announces Public ADS Offering
-
Amarin Announces Proposed Public Offering of American Depositary Shares
-
Pre-Open Stock Movers 03/09: (ATSG) (BUFF) (BETR) Higher; (STEM) (ZAGG) (DSX) Lower (more...)
-
Notable Analyst Rating Changes 3/12: (AMRN) (WIN) (VRSK) Upgraded; (ALKS) (CNX) (MSI) Downgraded
-
Pre-Open Stock Movers 03/12: (AMRN) (JASO) (UTX) Higher; (ACAD) (INGN) (INTC) Lower (more...)
-
Notable Analyst Rating Changes 2/18: (AMRN) (EXPR) (ROSE) Upgraded; (LLTC) (CTL) (FNGN) Downgraded

